Antimicrobial peptides as potential therapeutics for breast cancer
Breast cancer is the most common and deadliest cancer in women worldwide. Although notable advances have been achieved in the treatment of breast cancer, the overall survival rate of metastatic breast cancer patients is still considerably low due to the development of resistance to breast cancer che...
Gespeichert in:
| Veröffentlicht in: | Pharmacological research 2021-09, Vol.171, p.105777-105777, Article 105777 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 105777 |
|---|---|
| container_issue | |
| container_start_page | 105777 |
| container_title | Pharmacological research |
| container_volume | 171 |
| creator | Aghamiri, Shahin Zandsalimi, Farshid Raee, Pourya Abdollahifar, Mohammad-Amin Tan, Shing Cheng Low, Teck Yew Najafi, Sajad Ashrafizadeh, Milad Zarrabi, Ali Ghanbarian, Hossein Bandehpour, Mojgan |
| description | Breast cancer is the most common and deadliest cancer in women worldwide. Although notable advances have been achieved in the treatment of breast cancer, the overall survival rate of metastatic breast cancer patients is still considerably low due to the development of resistance to breast cancer chemotherapeutic agents and the non-optimal specificity of the current generation of cancer medications. Hence, there is a growing interest in the search for alternative therapeutics with novel anticancer mechanisms. Recently, antimicrobial peptides (AMPs) have gained much attention due to their cost-effectiveness, high specificity of action, and robust efficacy. However, there are no clinical data available about their efficacy. This warrants the increasing need for clinical trials to be conducted to assess the efficacy of this new class of drugs. Here, we will focus on the recent progress in the use of AMPs for breast cancer therapy and will highlight their modes of action. Finally, we will discuss the combination of AMP-based therapeutics with other breast cancer therapy strategies, including nanotherapy and chemotherapy, which may provide a potential avenue for overcoming drug resistance.
[Display omitted] |
| doi_str_mv | 10.1016/j.phrs.2021.105777 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2555104442</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1043661821003613</els_id><sourcerecordid>2555104442</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-814f292013a157ba032514a1d6ef9a52a243c51d986c7335774f5cd84ad758743</originalsourceid><addsrcrecordid>eNp9kEtPwzAQhC0EoqXwBzigHLmkeP3IQ-JSKl5SJS5wthxno7pqmmA7SPx7HKVw5LSr3ZmR5iPkGugSKGR3u2W_dX7JKIN4kHmen5A50DJLAYrsdNwFT7MMihm58H5HKS0F0HMy44KVBQCbk4fVIdjWGtdVVu-THvtga_SJ9knfBYzPeA1bdLrHIVjjk6ZzSeVQ-5AYfTDoLslZo_cer45zQT6eHt_XL-nm7fl1vdqkhssspAWIhpWMAtcg80pTziQIDXWGTakl00xwI6Eui8zknMc6opGmLoSuc1nkgi_I7ZTbu-5zQB9Ua73B_V4fsBu8YlLK2FgIFqVsksZe3jtsVO9sq923AqpGdmqnRnZqZKcmdtF0c8wfqhbrP8svrCi4nwQYW35ZdMobixFBbR2aoOrO_pf_Awe1ftQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2555104442</pqid></control><display><type>article</type><title>Antimicrobial peptides as potential therapeutics for breast cancer</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Aghamiri, Shahin ; Zandsalimi, Farshid ; Raee, Pourya ; Abdollahifar, Mohammad-Amin ; Tan, Shing Cheng ; Low, Teck Yew ; Najafi, Sajad ; Ashrafizadeh, Milad ; Zarrabi, Ali ; Ghanbarian, Hossein ; Bandehpour, Mojgan</creator><creatorcontrib>Aghamiri, Shahin ; Zandsalimi, Farshid ; Raee, Pourya ; Abdollahifar, Mohammad-Amin ; Tan, Shing Cheng ; Low, Teck Yew ; Najafi, Sajad ; Ashrafizadeh, Milad ; Zarrabi, Ali ; Ghanbarian, Hossein ; Bandehpour, Mojgan</creatorcontrib><description>Breast cancer is the most common and deadliest cancer in women worldwide. Although notable advances have been achieved in the treatment of breast cancer, the overall survival rate of metastatic breast cancer patients is still considerably low due to the development of resistance to breast cancer chemotherapeutic agents and the non-optimal specificity of the current generation of cancer medications. Hence, there is a growing interest in the search for alternative therapeutics with novel anticancer mechanisms. Recently, antimicrobial peptides (AMPs) have gained much attention due to their cost-effectiveness, high specificity of action, and robust efficacy. However, there are no clinical data available about their efficacy. This warrants the increasing need for clinical trials to be conducted to assess the efficacy of this new class of drugs. Here, we will focus on the recent progress in the use of AMPs for breast cancer therapy and will highlight their modes of action. Finally, we will discuss the combination of AMP-based therapeutics with other breast cancer therapy strategies, including nanotherapy and chemotherapy, which may provide a potential avenue for overcoming drug resistance.
[Display omitted]</description><identifier>ISSN: 1043-6618</identifier><identifier>EISSN: 1096-1186</identifier><identifier>DOI: 10.1016/j.phrs.2021.105777</identifier><identifier>PMID: 34298112</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Animals ; Anticancer peptides ; Antimicrobial peptides ; Antimicrobial Peptides - administration & dosage ; Antimicrobial Peptides - chemistry ; Antimicrobial Peptides - classification ; Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - chemistry ; Antineoplastic Agents - classification ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Breast cancer ; Breast Neoplasms - drug therapy ; Cancer therapy ; Combination therapy ; Drug Delivery Systems ; Female ; Humans</subject><ispartof>Pharmacological research, 2021-09, Vol.171, p.105777-105777, Article 105777</ispartof><rights>2021 Elsevier Ltd</rights><rights>Copyright © 2021 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-814f292013a157ba032514a1d6ef9a52a243c51d986c7335774f5cd84ad758743</citedby><cites>FETCH-LOGICAL-c356t-814f292013a157ba032514a1d6ef9a52a243c51d986c7335774f5cd84ad758743</cites><orcidid>0000-0001-7878-7534 ; 0000-0001-7226-5778 ; 0000-0002-0328-0023 ; 0000-0003-1083-1409</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1043661821003613$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34298112$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Aghamiri, Shahin</creatorcontrib><creatorcontrib>Zandsalimi, Farshid</creatorcontrib><creatorcontrib>Raee, Pourya</creatorcontrib><creatorcontrib>Abdollahifar, Mohammad-Amin</creatorcontrib><creatorcontrib>Tan, Shing Cheng</creatorcontrib><creatorcontrib>Low, Teck Yew</creatorcontrib><creatorcontrib>Najafi, Sajad</creatorcontrib><creatorcontrib>Ashrafizadeh, Milad</creatorcontrib><creatorcontrib>Zarrabi, Ali</creatorcontrib><creatorcontrib>Ghanbarian, Hossein</creatorcontrib><creatorcontrib>Bandehpour, Mojgan</creatorcontrib><title>Antimicrobial peptides as potential therapeutics for breast cancer</title><title>Pharmacological research</title><addtitle>Pharmacol Res</addtitle><description>Breast cancer is the most common and deadliest cancer in women worldwide. Although notable advances have been achieved in the treatment of breast cancer, the overall survival rate of metastatic breast cancer patients is still considerably low due to the development of resistance to breast cancer chemotherapeutic agents and the non-optimal specificity of the current generation of cancer medications. Hence, there is a growing interest in the search for alternative therapeutics with novel anticancer mechanisms. Recently, antimicrobial peptides (AMPs) have gained much attention due to their cost-effectiveness, high specificity of action, and robust efficacy. However, there are no clinical data available about their efficacy. This warrants the increasing need for clinical trials to be conducted to assess the efficacy of this new class of drugs. Here, we will focus on the recent progress in the use of AMPs for breast cancer therapy and will highlight their modes of action. Finally, we will discuss the combination of AMP-based therapeutics with other breast cancer therapy strategies, including nanotherapy and chemotherapy, which may provide a potential avenue for overcoming drug resistance.
[Display omitted]</description><subject>Animals</subject><subject>Anticancer peptides</subject><subject>Antimicrobial peptides</subject><subject>Antimicrobial Peptides - administration & dosage</subject><subject>Antimicrobial Peptides - chemistry</subject><subject>Antimicrobial Peptides - classification</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - chemistry</subject><subject>Antineoplastic Agents - classification</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Cancer therapy</subject><subject>Combination therapy</subject><subject>Drug Delivery Systems</subject><subject>Female</subject><subject>Humans</subject><issn>1043-6618</issn><issn>1096-1186</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEtPwzAQhC0EoqXwBzigHLmkeP3IQ-JSKl5SJS5wthxno7pqmmA7SPx7HKVw5LSr3ZmR5iPkGugSKGR3u2W_dX7JKIN4kHmen5A50DJLAYrsdNwFT7MMihm58H5HKS0F0HMy44KVBQCbk4fVIdjWGtdVVu-THvtga_SJ9knfBYzPeA1bdLrHIVjjk6ZzSeVQ-5AYfTDoLslZo_cer45zQT6eHt_XL-nm7fl1vdqkhssspAWIhpWMAtcg80pTziQIDXWGTakl00xwI6Eui8zknMc6opGmLoSuc1nkgi_I7ZTbu-5zQB9Ua73B_V4fsBu8YlLK2FgIFqVsksZe3jtsVO9sq923AqpGdmqnRnZqZKcmdtF0c8wfqhbrP8svrCi4nwQYW35ZdMobixFBbR2aoOrO_pf_Awe1ftQ</recordid><startdate>202109</startdate><enddate>202109</enddate><creator>Aghamiri, Shahin</creator><creator>Zandsalimi, Farshid</creator><creator>Raee, Pourya</creator><creator>Abdollahifar, Mohammad-Amin</creator><creator>Tan, Shing Cheng</creator><creator>Low, Teck Yew</creator><creator>Najafi, Sajad</creator><creator>Ashrafizadeh, Milad</creator><creator>Zarrabi, Ali</creator><creator>Ghanbarian, Hossein</creator><creator>Bandehpour, Mojgan</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7878-7534</orcidid><orcidid>https://orcid.org/0000-0001-7226-5778</orcidid><orcidid>https://orcid.org/0000-0002-0328-0023</orcidid><orcidid>https://orcid.org/0000-0003-1083-1409</orcidid></search><sort><creationdate>202109</creationdate><title>Antimicrobial peptides as potential therapeutics for breast cancer</title><author>Aghamiri, Shahin ; Zandsalimi, Farshid ; Raee, Pourya ; Abdollahifar, Mohammad-Amin ; Tan, Shing Cheng ; Low, Teck Yew ; Najafi, Sajad ; Ashrafizadeh, Milad ; Zarrabi, Ali ; Ghanbarian, Hossein ; Bandehpour, Mojgan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-814f292013a157ba032514a1d6ef9a52a243c51d986c7335774f5cd84ad758743</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Animals</topic><topic>Anticancer peptides</topic><topic>Antimicrobial peptides</topic><topic>Antimicrobial Peptides - administration & dosage</topic><topic>Antimicrobial Peptides - chemistry</topic><topic>Antimicrobial Peptides - classification</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - chemistry</topic><topic>Antineoplastic Agents - classification</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Cancer therapy</topic><topic>Combination therapy</topic><topic>Drug Delivery Systems</topic><topic>Female</topic><topic>Humans</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Aghamiri, Shahin</creatorcontrib><creatorcontrib>Zandsalimi, Farshid</creatorcontrib><creatorcontrib>Raee, Pourya</creatorcontrib><creatorcontrib>Abdollahifar, Mohammad-Amin</creatorcontrib><creatorcontrib>Tan, Shing Cheng</creatorcontrib><creatorcontrib>Low, Teck Yew</creatorcontrib><creatorcontrib>Najafi, Sajad</creatorcontrib><creatorcontrib>Ashrafizadeh, Milad</creatorcontrib><creatorcontrib>Zarrabi, Ali</creatorcontrib><creatorcontrib>Ghanbarian, Hossein</creatorcontrib><creatorcontrib>Bandehpour, Mojgan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pharmacological research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Aghamiri, Shahin</au><au>Zandsalimi, Farshid</au><au>Raee, Pourya</au><au>Abdollahifar, Mohammad-Amin</au><au>Tan, Shing Cheng</au><au>Low, Teck Yew</au><au>Najafi, Sajad</au><au>Ashrafizadeh, Milad</au><au>Zarrabi, Ali</au><au>Ghanbarian, Hossein</au><au>Bandehpour, Mojgan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antimicrobial peptides as potential therapeutics for breast cancer</atitle><jtitle>Pharmacological research</jtitle><addtitle>Pharmacol Res</addtitle><date>2021-09</date><risdate>2021</risdate><volume>171</volume><spage>105777</spage><epage>105777</epage><pages>105777-105777</pages><artnum>105777</artnum><issn>1043-6618</issn><eissn>1096-1186</eissn><abstract>Breast cancer is the most common and deadliest cancer in women worldwide. Although notable advances have been achieved in the treatment of breast cancer, the overall survival rate of metastatic breast cancer patients is still considerably low due to the development of resistance to breast cancer chemotherapeutic agents and the non-optimal specificity of the current generation of cancer medications. Hence, there is a growing interest in the search for alternative therapeutics with novel anticancer mechanisms. Recently, antimicrobial peptides (AMPs) have gained much attention due to their cost-effectiveness, high specificity of action, and robust efficacy. However, there are no clinical data available about their efficacy. This warrants the increasing need for clinical trials to be conducted to assess the efficacy of this new class of drugs. Here, we will focus on the recent progress in the use of AMPs for breast cancer therapy and will highlight their modes of action. Finally, we will discuss the combination of AMP-based therapeutics with other breast cancer therapy strategies, including nanotherapy and chemotherapy, which may provide a potential avenue for overcoming drug resistance.
[Display omitted]</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>34298112</pmid><doi>10.1016/j.phrs.2021.105777</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0001-7878-7534</orcidid><orcidid>https://orcid.org/0000-0001-7226-5778</orcidid><orcidid>https://orcid.org/0000-0002-0328-0023</orcidid><orcidid>https://orcid.org/0000-0003-1083-1409</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1043-6618 |
| ispartof | Pharmacological research, 2021-09, Vol.171, p.105777-105777, Article 105777 |
| issn | 1043-6618 1096-1186 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2555104442 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Animals Anticancer peptides Antimicrobial peptides Antimicrobial Peptides - administration & dosage Antimicrobial Peptides - chemistry Antimicrobial Peptides - classification Antineoplastic Agents - administration & dosage Antineoplastic Agents - chemistry Antineoplastic Agents - classification Antineoplastic Combined Chemotherapy Protocols - administration & dosage Breast cancer Breast Neoplasms - drug therapy Cancer therapy Combination therapy Drug Delivery Systems Female Humans |
| title | Antimicrobial peptides as potential therapeutics for breast cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T16%3A36%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antimicrobial%20peptides%20as%20potential%20therapeutics%20for%20breast%20cancer&rft.jtitle=Pharmacological%20research&rft.au=Aghamiri,%20Shahin&rft.date=2021-09&rft.volume=171&rft.spage=105777&rft.epage=105777&rft.pages=105777-105777&rft.artnum=105777&rft.issn=1043-6618&rft.eissn=1096-1186&rft_id=info:doi/10.1016/j.phrs.2021.105777&rft_dat=%3Cproquest_cross%3E2555104442%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2555104442&rft_id=info:pmid/34298112&rft_els_id=S1043661821003613&rfr_iscdi=true |